The study, led by Director of Medicinal Chemistry Elena Bray, details the first successful intermolecular carbon-to-carbon bonding at the 4-position of tryptamines. By utilizing 4-Br-DMT as an intermediate, the team can now access chemical spaces previously unavailable in the development of psychedelics such as psilocybin, N,N-DMT, and 5-MeO-DMT. While the compound itself is not a therapeutic, it serves as a critical tool for engineering derivative molecules.
In section Releases
Psilera Unlocks New Synthetic Pathways for Neuroplastogen Discovery
Tampa-based biopharmaceutical firm Psilera has unveiled a novel chemical synthesis method allowing for unprecedented structural modifications to tryptamine scaffolds. Published in ACS Omega, the research introduces 4-Br-DMT as a versatile building block, enabling the creation of diverse molecular libraries aimed at advancing next-generation neuroplastogen therapies.
This research, conducted in collaboration with the Designer Drug Research Unit at the National Institute on Drug Abuse, expands Psilera’s patent-protected pipeline beyond its current lead candidate, PSIL-006. Chief Scientific Officer Jackie von Salm noted that diversifying these chemical tools is essential for optimizing drug design and identifying the most promising therapeutic candidates for future clinical study.
Comments (0)
No comments yet. Be the first!